1.Study on the way of blocking the father-child 、mother-child transmission of hepatitis B virus by combination therapy
Weiqun KE ; Yuzhan SHEN ; Yong XIAO
Chinese Journal of Primary Medicine and Pharmacy 2011;18(1):32-34
Objective To study the way of blocking the father-child、mother-child transmission of HBV.Methods 387 fathers or mothers who were positive for HBV-DNA were divided into three groups according to the father and mother's HBV-DNA and anti-HBsAg. Then they were randomly divided into three groups,one group were treated by HBIG,the second group were treated by lamivudine,the third group were treated by HBIG and Lamivudine.90 of their children who were positive for HBV-DNA were randimly dinded into three groups,one group were treated by hepatitis B Vaccine,the second group were treated by hepatitis B Vaccine and HBIG,the third group were treated by hepatitis B Vaccine and Gm-CSF. Their serum HBV-DNA were tested by fluorescence quantitative - PCR method.Results After treatment on the fathers or mothers,the degree of HBV-DNA was decreased obviously. There were significant difference between the groups who were treated by HBIG and lamivudine and the group who were treated only by HBIG or lamivudine( P <0.05 ). The rate of their newborn with HBV-DNA( + ) were significantly lower then other groups. After treatment on the newborn with HBV-DNA( + ). The degree of HBV-DNA had significant difference between the groups who were treated by both drug and vaccine and the vaccine group(P <0.05). Conclusion The fathers or mothers with HBV-DNA( + ) were treated by HBIG、lamivudine before they want a child, and fheir newborn with HBV-DNA( + ) were treated by vaccine、HBIG、Gm-CSF. This was an important way to block the father-child、mother-child transmission of Hepatitis B Virus.
2.Clinical study of poractant alfa injection therapy for neonatal respiratory distress syndrome
Yuzhan SHEN ; Weiqun KE ; Yanxiu LIU
Chinese Journal of Primary Medicine and Pharmacy 2015;22(3):402-405
Objective To investigate the effect of poractant alfa injection(PS) on neonatal respiratory distress syndrome(NRDS).Methods According to the digital table,80 cases of NRDS were randomly divided into the control group (40 cases) and the treatment group (40 cases).Both two groups were treated by mechanical ventilation and conventional symptomatic,supportive treatment.The treatment group was given PS intratracheal injection,the control group was given 0.9% sodium chloride injection intratracheal injection.The clinical symptoms,blood gas analysis and the improvement of X-ray chest film were dynamicly observed,the clinical efficacy was compared between the two groups.Results In the treatment group,PaO2 returned to > 60mmHg time,PaCO2 returned to < 50mmHg time,mechanical ventilation time were (2.13 ± 0.21) h,(12.56 ± 0.11) h,(18.2 ± 0.33) h,which were shorter than those in the control group [(12.41 ± 0.13) h,(89.87 ± 0.26) h,(76.13 ± 0.65) h,t =2.632,2.403,1.895,all P < 0.05] ;39 cases in the treatment group were cured(97.5%),30 cases in the control group were cured(75.0%),the difference of cure rate between the two groups was statistically significant(x2 =8.53,P < 0.05).The incidence rate of comnplications such as pulnonary hemorrhage,pneumothorax,intracranial hemorrhage in the treatment group was 7.5%,which was significantly lower than 32.5% in the control group (x2 =7.81,P < 0.05).Conclusion PS in the treatment of NRDS has obvious curative effect and less adverse reactions,it can be used in clinical application.
3.Intervention effect of montelukast on thymus and activation-regulated chemokine in children with asthma
Weiqun KE ; Kuihua TAN ; Xiaojin YANG ; Yuzhan SHEN ; Yong XIAO ; Xiaochi HUANG
Chinese Journal of Primary Medicine and Pharmacy 2011;18(8):1052-1054
Objective To study the intervention effect of montelukast on thymus and activation-regulated chemokine(TARC) in the children with asthma.Methods 100 children with asthma were randomly divided into montelukast (LTRA) group ( n = 50) and budesonide (BUD) group ( n = 50), the LTRA group was treated with montelukast, the BUD group was treated with budesonide,50 children without asthma as control group were inhaled NS.Before and after 7 days treatment,the asthma symptoms, FEV1,concentration of TARC were measured.Results Before treatment,the concentration of TARC in asthma group was significantly higher than control group (P < 0.05 ).After treatment, the concentration of TARC in BUD group and LTRA group was significandy decreased( P < 0.05 ), but the difference between these two groups was not significantl( P > 0.05 ), the concentration of TARC in control group was not significantly decreased(P > 0.05 ) ;the symptoms were better after treatment in BUD group and LTRA group,(P <0,05) ,and the pulmonary function was significantly improved after treatment in BUD group and LTRA group ( P < 0.05 ).Conclusion TARC was the important factor in children asthma.Montelukast could block the production of TARC ,and was more convenient and safe for children asthma.
4.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.